<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1850" language="x-unspecified"/>
    <type:ORR xmi:id="13" sofa="6" begin="853" end="858"/>
    <type:PFSTime xmi:id="17" sofa="6" begin="1088" end="1094"/>
    <type:PFSTime xmi:id="33" sofa="6" begin="1240" end="1246"/>
    <type:OSTime xmi:id="21" sofa="6" begin="1088" end="1094"/>
    <type:PFSRate xmi:id="25" sofa="6" begin="1117" end="1122"/>
    <type:PFSRate xmi:id="37" sofa="6" begin="1294" end="1298"/>
    <type:PFSRate xmi:id="41" sofa="6" begin="1301" end="1304"/>
    <type:OSRate xmi:id="29" sofa="6" begin="1128" end="1133"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="PURPOSE: This single-center, open-label, phase II trial evaluated the bortezomib,&#13;&#10;pegylated liposomal doxorubicin (PLD), and dexamethasone combination regimen&#13;&#10;(VDD) as initial treatment for patients with newly diagnosed multiple myeloma&#13;&#10;(MM).&#13;&#10;PATIENTS AND METHODS: Enrolled patients (N = 40) received up to six 3-week cycles&#13;&#10;of treatment with bortezomib 1.3 mg/m(2) intravenously (IV) on days 1, 4, 8, and &#13;&#10;11; PLD 30 mg/m(2) IV on day 4; and dexamethasone 20 to 40 mg daily as specified &#13;&#10;in the study design. The primary end point was the complete/near-complete&#13;&#10;response (CR/nCR) rate after six cycles. Secondary end points included overall&#13;&#10;response rate (ORR), progression-free survival (PFS), and overall survival (OS). &#13;&#10;The impact of VDD on stem-cell mobilization and collection also was evaluated.&#13;&#10;RESULTS: After six cycles, the ORR was 85.0% (CR/nCR, 37.5%; very good partial&#13;&#10;response [VGPR] or better, 57.5%). Patients who underwent stem-cell&#13;&#10;transplantation (SCT) after VDD (n = 30) experienced increased rates of VGPR or&#13;&#10;better (53.3% to 76.6% after SCT). Overall, 1-year PFS and OS rates were 92.5%&#13;&#10;and 97.5%, respectively. Those who achieved VGPR or better after treatment with&#13;&#10;VDD showed a significantly greater 1-year PFS versus those who achieved less than&#13;&#10;VGPR (100% v 82%, respectively; P = .03). Similar results were observed in&#13;&#10;patients who underwent SCT. Grades 3 or 4 hematologic toxicities occurred in &lt; or&#13;&#10;= 10% of patients; grade 2 painful neuropathy occurred in 7.5%; and grade 3&#13;&#10;palmar-plantar erythrodysesthesia occurred in 2.5%.&#13;&#10;CONCLUSION: VDD is highly effective for initial treatment of MM followed by SCT&#13;&#10;in appropriate patients, and it has a reasonable safety profile. Achievement of&#13;&#10;VGPR or better with this initial therapy predicted longer PFS, regardless of the &#13;&#10;consolidation therapy given."/>
    <cas:View sofa="6" members="1 13 17 33 21 25 37 41 29"/>
</xmi:XMI>
